BOYNTON BEACH, Fla., Dec. 10, 2003 (PRIMEZONE) -- Harvey Grossman, President and Chief Strategic Officer of Jacobson Resonance Enterprises, Inc. (OTCBB:JRSE) announces today the Company's estimated USA revenue projections for the Veterinary Medicine market space for the years 2005 through 2008. These projections are based on our rebuilt management team's current analysis of market trends. The projections flow from our newly identified target markets, reasonable time lines for execution, and a growing scientific and technology base. We believe that our business model for 2004 and 2005 is important as this acts as a launching pad for subsequent success.
USA Veterinary Medicine -- There are 22,000 veterinary hospitals and 80,000 licensed veterinarians in the USA. A 1995 marketing study by the American Animal Hospital Association detailed a market of between 115-120 million companion animals (dogs and cats) in the United States for which animal owners spent some $20 billion for pet related products and services. The study also detailed that of the 65 million households 58.5% owned pets and 76% of these considered the animal part of the family. The medical services component of the market, that is, those services dispensed by a licensed veterinarian, accounted for $11 billion in 2001 and continues to grow.
Preliminary studies by JRSE at Mississippi State University and other sites indicate the efficacy for the treatment of horses and other animals in pain management and other indications is analogous to humans as gleaned from European and Canadian clinical data. With no regulatory approvals necessary in this market segment, JRSE plans to tap into this segment in 2004/2005 as we show modest revenues beginning in 2005. Initial, promising discussions are ongoing with Veterinarians who are keenly interested in introducing Jacobson Resonance into the veterinary arena. We will begin in the equine area by producing in 2004 several second-generation prototype resonators for the alleviation of pain, inflammation and to speed wound healing. In addition, studies with dogs at the University of Oklahoma have yielded data that indicates the possibility of affecting vagosympathetic balance for the cardiovascular system. This might have ramifications that extend to the racing of dogs and horses.
JRSE Revenue Projections For Veterinary Medicine, 2004 - 2008
2005 2006 2007 2008
------- ------- ------- -------
(1) USA Veterinary Medicine 150,000 250,000 400,000 600,000
JRSE is an emerging worldwide leader in magnetic resonance technology, whose main focus is the eradication of human suffering. The Company's technology base has the potential for multiple industry applications including the fields of medicine, spa and leisure arena, food and beverage, pharmaceuticals, energy and the environment.
(1) Although we have set what we believe is a responsible goal there is no assurance that we will achieve this anticipated market penetration. We recognize that there is competition in this marketplace, and that to achieve our goal, we will need to establish significant revenue streams to avoid the need for additional funding.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The matters covered by such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of the Company to differ materially from those contemplated or implied by such forward-looking statements. Included in these risks and other factors are funding availability, competition from better-financed companies and required regulatory clearances.